The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Search articles by EPIC code

Fusion Antibodies – results argue “significant progress”, so why more than 7% share price decline?...

2021-08-10 11:25:16

Fusion Antibodies (FAB) has announced results for its year ended 31st March 2021 emphasising “significant progress with sustained revenue growth, progress on the R&D pipeline, and continue to expand our range of services”. So why are the shares, at 125p, currently more than 7% lower in response?...


Fusion Antibodies – argues some “excellent progress”… so why has the covid bandwagon currently de-railed somewhat here?

2020-07-06 11:41:56

Fusion Antibodies (FAB) has updated with CEO Paul Kerr emphasising “distributor agreements will broaden our reach in two key markets” and “generated a panel of SARS-CoV-2 S antigens”. The covid bandwagon has though currently de-railed somewhat here – the shares presently back below 90p, down 14%...


Fusion Antibodies – director share sale further supporting my stance?

2020-02-03 16:02:23

Last week I cautioned on shares in Fusion Antibodies (FAB), with they above 90p on the back of a “Trading update”. Today a “Director/PDMR Shareholding” announcement…


Fusion Antibodies – emphasises “strong revenue performance”… what about cash burn?

2020-01-29 14:20:46

Previously I’ve cautioned on shares in “specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications”, Fusion Antibodies (FAB). They have recently though again been rising – and today a “Trading update”


Fusion Antibodies – emphasises second half improvement… why a muted share price response?

2019-04-18 15:00:39

“Fusion Antibodies plc (AIM: FAB), a pharmaceutical contract research organisation specialising in antibody engineering services, provides a business and unaudited trading update for year ended 31 March 2019, confirming the improvement in second half performance announced on 25 February 2019”. Sounds positive – though despite being down from more than 100p in August and even a start of 2019 more than 50p, the shares nudging up to only 30p?...


Fusion Antibodies – “materially below current market expectations” adds to “significantly behind” expectations from earlier in the year!

2019-02-25 04:00:39

“Fusion Antibodies plc (AIM: FAB), a pharmaceutical contract research organisation specialising in antibody engineering services, provides an update on the company's trading and progress to date in the current financial year ending 31 March 2019”. This is a company which listed in December 2017, with house broker Allenby Capital looking for revenue of £3.2 million for the company’s year ended 31st March 2018 and breaking into profit on revenue of £5.6 million for the now current year…


Fusion Antibodies – “delighted” to present annual report following “successful” admission. Really?

2018-08-16 14:40:18

Fusion Antibodies (FAB) Chairman Dr Simon Douglas is “delighted to present the first annual report for the company following our successful admission to AIM in December 2017”. Hmmm - the shares are down on the announcement at 75p, comparing to a 82p listing price. “Delighted” and “successful”, you say?...


Fusion Antibodies – from “positive outlook” to “significantly behind” expectations in little more than 5 months (& within 8 months of listing)!

2018-08-13 10:35:39

A trading update from Fusion Antibodies (FAB) commences that it “announces that the company's results for the year ended 31 March 2018 will be announced on 16 August 2018. The results for FY18 are in line with current market expectations”. Hmmm – but it updated in March including “at least 40% revenue growth expected; adj EBITDA broadly in-line with expectations”, so why is the latest update needed so soon before the results announcement?...


About ShareProphets

Contact Us

Advertise With Us

Send Us A Tip


Terms of Service

Privacy Policy

Cookie Policy

Forgot My Password

Forgot My Username

Resend Account Validation Token

Site by Everywhen